URGN vs WHWK
URGN: UroGen Pharma is transforming the treatment of urothelial cancers with its proprietary hydrogel technology that allows for non-surgical, sustained-release drug delivery. WHWK: Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload technology.
Side-by-side fundamentals
| Metric | URGN | WHWK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $42.06 | $3.99 | |
| Market cap as of 2026-07-23 | $2.1B | $216M | |
| Net margin as of 2026-07-23 | -94.8% | +99.4% | WHWK higher |
| Gross margin as of 2026-07-23 | +89.8% | +88.7% | URGN higher |
| Operating margin as of 2026-07-23 | -77.0% | +87.4% | WHWK higher |
| ROE as of 2026-07-23 | -204.5% | -79.6% | WHWK higher |
| ROA as of 2026-07-23 | -62.8% | -74.0% | URGN higher |
| Debt / equity as of 2026-07-23 | 4.77 | 0.00 | WHWK lower |
| Revenue growth (YoY) as of 2026-07-23 | +52.9% | -22.3% | URGN higher |
| Revenue CAGR (3y) SEC XBRL | +19.5% | -22.3% | URGN higher |
| Beta as of 2026-07-23 | 1.53 | 0.81 | |
| 1-year return as of 2026-07-22 close | +148.0% | +113.4% | URGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.